Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 370

1.

Sub-classifying patients with mild traumatic brain injury: A clustering approach based on baseline clinical characteristics and 90-day and 180-day outcomes.

Si B, Dumkrieger G, Wu T, Zafonte R, Valadka AB, Okonkwo DO, Manley GT, Wang L, Dodick DW, Schwedt TJ, Li J.

PLoS One. 2018 Jul 11;13(7):e0198741. doi: 10.1371/journal.pone.0198741. eCollection 2018.

2.

Vancouver Declaration on Global Headache Patient Advocacy 2018.

Dodick D, Edvinsson L, Makino T, Grisold W, Sakai F, Jensen R, Balch A, Ruiz de la Torre E, Henscheid-Lorenz D, Craven A, Ashina M; International Headache Society Global Patient Advocacy Coalition.

Cephalalgia. 2018 Jan 1:333102418781644. doi: 10.1177/0333102418781644. [Epub ahead of print]

PMID:
29882695
3.

Evaluation of Galcanezumab for the Prevention of Episodic Migraine: The EVOLVE-1 Randomized Clinical Trial.

Stauffer VL, Dodick DW, Zhang Q, Carter JN, Ailani J, Conley RR.

JAMA Neurol. 2018 May 29. doi: 10.1001/jamaneurol.2018.1212. [Epub ahead of print]

PMID:
29813147
4.

Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial.

Dodick DW, Silberstein SD, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, Grozinski-Wolff M, Yang R, Ma Y, Aycardi E.

JAMA. 2018 May 15;319(19):1999-2008. doi: 10.1001/jama.2018.4853.

PMID:
29800211
5.

Factors associated with acute medication overuse in people with migraine: results from the 2017 migraine in America symptoms and treatment (MAST) study.

Schwedt TJ, Alam A, Reed ML, Fanning KM, Munjal S, Buse DC, Dodick DW, Lipton RB.

J Headache Pain. 2018 May 24;19(1):38. doi: 10.1186/s10194-018-0865-z.

6.

Use of Most Bothersome Symptom as a Coprimary Endpoint in Migraine Clinical Trials: A Post-Hoc Analysis of the Pivotal ZOTRIP Randomized, Controlled Trial.

Dodick DW, Tepper SJ, Friedman DI, Gelfand AA, Kellerman DJ, Schmidt PC.

Headache. 2018 May 21. doi: 10.1111/head.13327. [Epub ahead of print]

PMID:
29782049
7.

The Effect of OnabotulinumtoxinA on Aura Frequency and Severity in Patients With Hemiplegic Migraine: Case Series of 11 Patients.

Chen TY, Garza I, Dodick DW, Robertson CE.

Headache. 2018 May 15. doi: 10.1111/head.13317. [Epub ahead of print]

PMID:
29762872
8.

Sustained reductions in migraine days, moderate-to-severe headache days and days with acute medication use for HFEM and CM patients taking fremanezumab: Post-hoc analyses from phase 2 trials.

Halker Singh RB, Aycardi E, Bigal ME, Loupe PS, McDonald M, Dodick DW.

Cephalalgia. 2018 Jan 1:333102418772585. doi: 10.1177/0333102418772585. [Epub ahead of print]

PMID:
29722276
9.

Treatment of Cluster Headache.

Kingston WS, Dodick DW.

Ann Indian Acad Neurol. 2018 Apr;21(Suppl 1):S9-S15. doi: 10.4103/aian.AIAN_17_18. Review.

10.

A Phase-by-Phase Review of Migraine Pathophysiology.

Dodick DW.

Headache. 2018 May;58 Suppl 1:4-16. doi: 10.1111/head.13300.

PMID:
29697154
11.

Estimating the clinical effectiveness and value-based price range of erenumab for the prevention of migraine in patients with prior treatment failures: a US societal perspective.

Lipton RB, Brennan A, Palmer S, Hatswell AJ, Porter JK, Sapra S, Villa G, Shah N, Tepper S, Dodick D.

J Med Econ. 2018 Jul;21(7):666-675. doi: 10.1080/13696998.2018.1457533. Epub 2018 Apr 3.

PMID:
29571276
12.

Migraine.

Dodick DW.

Lancet. 2018 Mar 31;391(10127):1315-1330. doi: 10.1016/S0140-6736(18)30478-1. Epub 2018 Mar 6. Review.

PMID:
29523342
13.

A multicenter, prospective, single arm, open label, observational study of sTMS for migraine prevention (ESPOUSE Study).

Starling AJ, Tepper SJ, Marmura MJ, Shamim EA, Robbins MS, Hindiyeh N, Charles AC, Goadsby PJ, Lipton RB, Silberstein SD, Gelfand AA, Chiacchierini RP, Dodick DW.

Cephalalgia. 2018 May;38(6):1038-1048. doi: 10.1177/0333102418762525. Epub 2018 Mar 4.

14.

Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults.

Tassorelli C, Diener HC, Dodick DW, Silberstein SD, Lipton RB, Ashina M, Becker WJ, Ferrari MD, Goadsby PJ, Pozo-Rosich P, Wang SJ; International Headache Society Clinical Trials Standing Committee.

Cephalalgia. 2018 Apr;38(5):815-832. doi: 10.1177/0333102418758283. Epub 2018 Mar 4.

PMID:
29504482
15.

ARISE: A Phase 3 randomized trial of erenumab for episodic migraine.

Dodick DW, Ashina M, Brandes JL, Kudrow D, Lanteri-Minet M, Osipova V, Palmer K, Picard H, Mikol DD, Lenz RA.

Cephalalgia. 2018 May;38(6):1026-1037. doi: 10.1177/0333102418759786. Epub 2018 Feb 22.

PMID:
29471679
16.

Measurement and implications of the distance between the sphenopalatine ganglion and nasal mucosa: a neuroimaging study.

Crespi J, Bratbak D, Dodick D, Matharu M, Jamtøy KA, Aschehoug I, Tronvik E.

J Headache Pain. 2018 Feb 13;19(1):14. doi: 10.1186/s10194-018-0843-5.

17.

King-Devick Test identifies real-time concussion and asymptomatic concussion in youth athletes.

Dhawan PS, Leong D, Tapsell L, Starling AJ, Galetta SL, Balcer LJ, Overall TL, Adler JS, Halker-Singh RB, Vargas BB, Dodick D.

Neurol Clin Pract. 2017 Dec;7(6):464-473. doi: 10.1212/CPJ.0000000000000381.

PMID:
29431168
18.

Lateralized kappa opioid receptor signaling from the amygdala central nucleus promotes stress-induced functional pain.

Nation KM, De Felice M, Hernandez PI, Dodick DW, Neugebauer V, Navratilova E, Porreca F.

Pain. 2018 May;159(5):919-928. doi: 10.1097/j.pain.0000000000001167.

PMID:
29369967
19.

Depicting the pterygopalatine ganglion on 3 Tesla magnetic resonance images.

Bratbak DF, Folvik M, Nordgård S, Stovner LJ, Dodick DW, Matharu M, Tronvik E.

Surg Radiol Anat. 2018 Jun;40(6):689-695. doi: 10.1007/s00276-017-1960-6. Epub 2017 Dec 22.

PMID:
29274037
20.

Academic dissertations from the Danish Headache Center 1980-2016.

Dodick DW.

Cephalalgia. 2017 Dec;37(2_suppl):3. doi: 10.1177/0333102417724937. No abstract available.

PMID:
29256258
21.

Effect of Different Doses of Galcanezumab vs Placebo for Episodic Migraine Prevention: A Randomized Clinical Trial.

Skljarevski V, Oakes TM, Zhang Q, Ferguson MB, Martinez J, Camporeale A, Johnson KW, Shan Q, Carter J, Schacht A, Goadsby PJ, Dodick DW.

JAMA Neurol. 2018 Feb 1;75(2):187-193. doi: 10.1001/jamaneurol.2017.3859.

22.

Fremanezumab for the Preventive Treatment of Chronic Migraine.

Silberstein SD, Dodick DW, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, Grozinski-Wolff M, Yang R, Ma Y, Aycardi E.

N Engl J Med. 2017 Nov 30;377(22):2113-2122. doi: 10.1056/NEJMoa1709038.

23.

The emerging role of gammaCore® in the management of cluster headache: expert panel recommendations.

Silberstein SD, Calhoun AH, Treppendahl C, Dodick DW, Rapoport AM, Mamidi A, Vargas P, Ebert TH, Tepper SJ.

Am J Manag Care. 2017 Nov;23(17 Suppl):S326-S333.

24.

Board Walk - September 2017.

Dodick DW.

Cephalalgia. 2017 Sep;37(10):1009-1010. doi: 10.1177/0333102417722483. No abstract available.

PMID:
28885053
25.

Fremanezumab as Add-On Treatment for Patients Treated With Other Migraine Preventive Medicines.

Cohen JM, Dodick DW, Yang R, Newman LC, Li T, Aycardi E, Bigal ME.

Headache. 2017 Oct;57(9):1375-1384. doi: 10.1111/head.13156. Epub 2017 Sep 1.

PMID:
28862758
26.

Erenumab (AMG 334) in episodic migraine: Interim analysis of an ongoing open-label study.

Ashina M, Dodick D, Goadsby PJ, Reuter U, Silberstein S, Zhang F, Gage JR, Cheng S, Mikol DD, Lenz RA.

Neurology. 2017 Sep 19;89(12):1237-1243. doi: 10.1212/WNL.0000000000004391. Epub 2017 Aug 23.

PMID:
28835404
27.

Re: Placebo responses in device studies.

Goadsby PJ, Dodick DW, Lipton RB.

Cephalalgia. 2018 Apr;38(5):1007-1008. doi: 10.1177/0333102417722498. Epub 2017 Jul 26. No abstract available.

PMID:
28747062
28.

Insights into the Functional Anatomy Behind the PREEMPT Injection Paradigm: Guidance on Achieving Optimal Outcomes.

Blumenfeld AM, Silberstein SD, Dodick DW, Aurora SK, Brin MF, Binder WJ.

Headache. 2017 May;57(5):766-777. doi: 10.1111/head.13074. Epub 2017 Apr 6.

29.

Kappa opioid receptor antagonists: A possible new class of therapeutics for migraine prevention.

Xie JY, De Felice M, Kopruszinski CM, Eyde N, LaVigne J, Remeniuk B, Hernandez P, Yue X, Goshima N, Ossipov M, King T, Streicher JM, Navratilova E, Dodick D, Rosen H, Roberts E, Porreca F.

Cephalalgia. 2017 Jul;37(8):780-794. doi: 10.1177/0333102417702120. Epub 2017 Apr 4.

PMID:
28376659
30.

The Effect of In-School Saccadic Training on Reading Fluency and Comprehension in First and Second Grade Students.

Dodick D, Starling AJ, Wethe J, Pang Y, Messner LV, Smith C, Master CL, Halker-Singh RB, Vargas BB, Bogle JM, Mandrekar J, Talaber A, Leong D.

J Child Neurol. 2017 Jan;32(1):104-111. doi: 10.1177/0883073816668704. Epub 2016 Oct 10.

PMID:
28257277
31.

The Non-Inferiority Margins in Migraine Research (NIMM) Survey.

Orr SL, Ramsay T, Christie SN, Dodick D, Gladstone J, Dowlatshahi D.

Headache. 2017 May;57(5):729-736. doi: 10.1111/head.13048. Epub 2017 Feb 11.

PMID:
28188613
32.

Concussion in Ice Hockey: Current Gaps and Future Directions in an Objective Diagnosis.

Smith AM, Stuart MJ, Roberts WO, Dodick DW, Finnoff JT, Jorgensen JK, Krause DA.

Clin J Sport Med. 2017 Sep;27(5):503-509. doi: 10.1097/JSM.0000000000000412. Review.

PMID:
28079758
33.

Efficacy of (S)-Lacosamide in preclinical models of cephalic pain.

Moutal A, Eyde N, Telemi E, Park KD, Xie JY, Dodick DW, Porreca F, Khanna R.

Pain Rep. 2016 Jun;1(1). pii: e565.

34.

Anatomy and immunochemical characterization of the non-arterial peptidergic diffuse dural innervation of the rat and Rhesus monkey: Implications for functional regulation and treatment in migraine.

Rice FL, Xie JY, Albrecht PJ, Acker E, Bourgeois J, Navratilova E, Dodick DW, Porreca F.

Cephalalgia. 2017 Dec;37(14):1350-1372. doi: 10.1177/0333102416677051. Epub 2016 Nov 16.

PMID:
27852962
35.

Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: A retrospective claims analysis.

Hepp Z, Dodick DW, Varon SF, Chia J, Matthew N, Gillard P, Hansen RN, Devine EB.

Cephalalgia. 2017 Apr;37(5):470-485. doi: 10.1177/0333102416678382. Epub 2016 Nov 12.

36.

United States National Pain Strategy for Population Research: Concepts, Definitions, and Pilot Data.

Von Korff M, Scher AI, Helmick C, Carter-Pokras O, Dodick DW, Goulet J, Hamill-Ruth R, LeResche L, Porter L, Tait R, Terman G, Veasley C, Mackey S.

J Pain. 2016 Oct;17(10):1068-1080. doi: 10.1016/j.jpain.2016.06.009. Epub 2016 Jul 1.

PMID:
27377620
37.

TEV-48125 for the preventive treatment of chronic migraine: Efficacy at early time points.

Bigal ME, Dodick DW, Krymchantowski AV, VanderPluym JH, Tepper SJ, Aycardi E, Loupe PS, Ma Y, Goadsby PJ.

Neurology. 2016 Jul 5;87(1):41-8. doi: 10.1212/WNL.0000000000002801. Epub 2016 Jun 8.

38.

A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine.

Voss T, Lipton RB, Dodick DW, Dupre N, Ge JY, Bachman R, Assaid C, Aurora SK, Michelson D.

Cephalalgia. 2016 Aug;36(9):887-98. doi: 10.1177/0333102416653233. Epub 2016 Jun 6.

PMID:
27269043
39.

Prevention of stress- or nitric oxide donor-induced medication overuse headache by a calcitonin gene-related peptide antibody in rodents.

Kopruszinski CM, Xie JY, Eyde NM, Remeniuk B, Walter S, Stratton J, Bigal M, Chichorro JG, Dodick D, Porreca F.

Cephalalgia. 2017 May;37(6):560-570. doi: 10.1177/0333102416650702. Epub 2016 May 19.

PMID:
27206958
40.

Migraine: What Imaging Reveals.

Chong CD, Schwedt TJ, Dodick DW.

Curr Neurol Neurosci Rep. 2016 Jul;16(7):64. doi: 10.1007/s11910-016-0662-5. Review.

PMID:
27181270
41.

Pilot study of sphenopalatine injection of onabotulinumtoxinA for the treatment of intractable chronic migraine.

Bratbak DF, Nordgård S, Stovner LJ, Linde M, Dodick DW, Aschehoug I, Folvik M, Tronvik E.

Cephalalgia. 2017 Apr;37(4):356-364. doi: 10.1177/0333102416648328. Epub 2016 May 6.

42.

Assessing Barriers to Chronic Migraine Consultation, Diagnosis, and Treatment: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study.

Dodick DW, Loder EW, Manack Adams A, Buse DC, Fanning KM, Reed ML, Lipton RB.

Headache. 2016 May 3. doi: 10.1111/head.12774. [Epub ahead of print]

43.

Impact of Migraine on the Family: Perspectives of People With Migraine and Their Spouse/Domestic Partner in the CaMEO Study.

Buse DC, Scher AI, Dodick DW, Reed ML, Fanning KM, Manack Adams A, Lipton RB.

Mayo Clin Proc. 2016 Apr 25. pii: S0025-6196(16)00126-9. doi: 10.1016/j.mayocp.2016.02.013. [Epub ahead of print]

44.

Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial.

Sun H, Dodick DW, Silberstein S, Goadsby PJ, Reuter U, Ashina M, Saper J, Cady R, Chon Y, Dietrich J, Lenz R.

Lancet Neurol. 2016 Apr;15(4):382-90. doi: 10.1016/S1474-4422(16)00019-3. Epub 2016 Feb 12.

PMID:
26879279
45.

Headache research in 2015: progress in migraine treatment.

Diener HC, Dodick DW.

Lancet Neurol. 2016 Jan;15(1):4-5. doi: 10.1016/S1474-4422(15)00341-5. Epub 2015 Dec 8. Review. No abstract available.

PMID:
26700894
46.
47.

Letter from the Editor-in-Chief.

Dodick DW.

Cephalalgia. 2015 Dec;35(14):1239. doi: 10.1177/0333102415616976. No abstract available.

PMID:
26574595
48.

Reply to Dr. Merry's Letter to the Editor.

Dilli E, Dodick D.

Cephalalgia. 2016 Aug;36(9):910. doi: 10.1177/0333102415616875. Epub 2015 Nov 12. No abstract available.

PMID:
26566934
49.

Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study.

Bigal ME, Dodick DW, Rapoport AM, Silberstein SD, Ma Y, Yang R, Loupe PS, Burstein R, Newman LC, Lipton RB.

Lancet Neurol. 2015 Nov;14(11):1081-90. doi: 10.1016/S1474-4422(15)00249-5. Epub 2015 Sep 30.

PMID:
26432182
50.

Occipital Nerve Stimulation for Migraine: Update from Recent Multicenter Trials.

Schwedt TJ, Green AL, Dodick DW.

Prog Neurol Surg. 2015;29:117-26. doi: 10.1159/000434662. Epub 2015 Sep 4. Review.

PMID:
26393345

Supplemental Content

Loading ...
Support Center